← Back to Clinical Trials
Recruiting NCT06825104

NCT06825104 Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06825104
Status Recruiting
Phase
Sponsor Volta Medical
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 278 participants
Start Date 2025-03-06
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Volta AF-XplorerDispersion ablation + PVIPVI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 278 participants in total. It began in 2025-03-06 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The TAILORED-LT study is conducted as an extension follow-up until 5 years of the initial TAILORED-AF study (NCT04702451), in order to demonstrate the long-term superiority in terms of freedom of atrial fibrillation (AF) of a tailored ablation strategy targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary veins isolation (PVI) over an anatomical ablation strategy targeting PVI alone for the initial ablation procedure of persistent AF.

Eligibility Criteria

Inclusion Criteria: * Patient who participated in the Tailored AF study * Patient not withdrawn during the 12-month follow-up period post-index procedure in the Tailored AF study * Patient able and willing to provide written informed consent to participate in this extension Tailored-LT study Exclusion Criteria: * Person deprived of liberty or under guardianship * Person unable to undergo a medical monitoring for geographical, social or psychological reasons

Contact & Investigator

Central Contact

Paola MILPIED

✉ paola.milpied@volta-medical.com

📞 (0)768025499

Principal Investigator

Isabel DEISENHOFER, MD

PRINCIPAL INVESTIGATOR

Deutsches Herzzentrum Muenchen

Frequently Asked Questions

Who can join the NCT06825104 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06825104 currently recruiting?

Yes, NCT06825104 is actively recruiting participants. Contact the research team at paola.milpied@volta-medical.com for enrollment information.

Where is the NCT06825104 trial being conducted?

This trial is being conducted at Bron, France, Clermont-Ferrand, France, Lomme, France, Marseille, France and 9 additional locations.

Who is sponsoring the NCT06825104 clinical trial?

NCT06825104 is sponsored by Volta Medical. The principal investigator is Isabel DEISENHOFER, MD at Deutsches Herzzentrum Muenchen. The trial plans to enroll 278 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology